



Published in final edited form as:

*J Am Chem Soc.* 2007 November 14; 129(45): 13778–13779. doi:10.1021/ja074864x.

## Redox Potential Control by Drug Binding to Cytochrome P450 3A4

Aditi Das<sup>‡</sup>, Yelena V. Grinkova<sup>‡</sup>, and Stephen G. Sligar<sup>‡, \*</sup>

<sup>‡</sup>*Departments of Biochemistry and Chemistry and Beckman Institute for Advanced Science and Technology  
University of Illinois Urbana-Champaign, Urbana, Illinois 61801*

### Abstract

The cytochrome P450s are ubiquitous heme proteins that utilize two reducing equivalents to cleave a ferrous iron - dioxygen complex to produce a single water molecule with the insertion of one oxygen atom into a bound substrate. For the case of soluble cytochrome P450 CYP101, it has been shown that there is a linear free energy relationship between heme redox potential and the spin state of the ferric protein. However, the universality of this relationship has been challenged in the case of mammalian enzymes. Most cytochrome P450s are integral membrane proteins, and detailed redox potential measurements have proved difficult due protein aggregation or the necessary presence of detergent. In this communication we utilize a soluble nanometer scale membrane bilayer disc (Nanodisc) to stabilize monomeric human cytochrome P450 CYP3A4. The Nanodisc system allows facile redox potential measurements to be made on substrate-free CYP3A4 as well as with several drug molecules bound at the active site. We show that substrate binding can dramatically effect the redox potential of the heme protein through modulation of the ferric spin state. A linear free energy relationship is observed, analogous to that noted for the soluble P450s, indicating a common mechanism for this linkage and providing a means for control of electron input in response to the presence of a metabolizable substrate, this potentially limiting the unwanted production of reduced oxygen species.

---

Human cytochrome P450s play the most critical role in drug metabolism. There are multiple P450s in the liver and the exact control of redox potential by drug binding to the cytochrome P450s is not well understood. For an effective physiological function of the numerous human P450s, understanding the mechanism of control of redox events on substrate binding is critical. Hepatic cytochrome P450 3A4 (CYP3A4) is a membrane bound cytochrome P450 involved in the metabolization of almost 50% of currently available drug molecules in humans.<sup>1</sup> The control of redox potential via drug binding to CYP3A4, studied herein, offers an elegant means of linking the utilization of pyridine nucleotide derived reducing equivalents to efficient substrate metabolism and thus avoiding the production of unwanted reduced oxygen species that could be deleterious to the organism.

For most soluble bacterial P450s, redox measurements have shown a correlation between the substrate induced shifts in the ferric spin state of the heme iron and the redox potential of the protein.<sup>2, 3</sup> In fact, the basic thermodynamic spin state control of redox potential has been shown to be true for many heme proteins.<sup>2, 4</sup> However, numerous studies on the redox potential control by substrate binding to membrane bound CYP proteins (in detergents and liposomes) have claimed that the redox potential of membrane bound cytochrome P450s show little if any dependence on the binding of substrates<sup>5</sup>, the mitochondrial CYP11A1 being an exception.<sup>6</sup> In particular, previous studies on detergent solubilized CYP3A4 have suggested that there is no change in redox potential of the protein on binding substrates such as testosterone and ethylmorphine, although a change in the ferric spin equilibrium is observed.<sup>5b</sup> These studies

---

\*s-sligar@uiuc.edu.

have lead to the speculations that substrate binding, spin state and redox potential, which have been shown to be linked for soluble bacterial P450s, is not applicable to the important CYPs involved in drug metabolism.

In this communication, we measure the solution redox potential of CYP3A4 in a native-like membrane bilayer mimic (Nanodisc). The Nanodisc provides an ideal environment for generating active, soluble and monodisperse integral membrane proteins and avoids potential aggregation that could make redox potential measurements difficult.<sup>7</sup> We show that the redox potential of CYP3A4 in Nanodiscs can be correlated with the spin equilibrium constants of the ferric heme protein, analogous to that observed for CYP101 in solution, yielding a coherent understanding of metabolic regulation in the cytochrome P450s.

The assembly of CYP3A4 in Nanodiscs yields a 1:1 ratio of CYP3A4 to the nanobilayer and represents a homogeneous and monomeric population.<sup>8</sup> Previously, it has been shown that bromocriptine (BC) and testosterone (TST) binding to CYP3A4-Nanodiscs induce a > 90% spin conversion to the high spin ( $S=5/2$ ) state<sup>8a</sup> compared to an incomplete high spin conversion in various reconstituted or detergent solubilized systems.<sup>9</sup> Other substrates, such as erythromycin (ERY), yield only 22% high spin content when bound to CYP3A4-Nanodiscs (supporting information). Hence, the change in redox potential on binding these substrates can be used to define the linkage of substrate binding, ferric spin state and overall redox potential change in membrane bound cytochrome CYP3A4.

Spectro-potentiometric titrations of CYP3A4-Nanodisc employed Dutton's method in the presence of standard mediators.<sup>11</sup> Figure 1A shows that on reduction, for both the substrate free and bound oxidized CYP3A4-Nanodiscs, there are transitions in both Soret and Q-band region. The fraction of the reduced protein as calculated from the spectral components is plotted against the applied potential in figure 1C. From figure 1D (Nernst plot)<sup>10</sup>, the midpoint potential of the protein is calculated and the values are reported in Table 1.

The binding of the Type I substrates TST and BC leads to a significant increase in the high spin content, accompanied by an increase in redox potential of  $\sim + 80$  mV. The nanoscale bilayer environment allows clean measurement of redox potentials of the membrane protein due to increased stability of the monomeric CYP3A4 and the absence of aggregation or presence of detergents which can alter the physical state of the CYP3A4 heme protein.

Key factors leading to the difference in redox potentials of the substrate free and bound P450 include the difference in ligand field stabilization energy between low spin (LS) and high spin (HS) ferric heme, the conformational change in the protein and the change in the local dielectric<sup>12</sup> around the heme. In CYP3A4, the coordination of water at the sixth distal ligand position can stabilize the LS hexa-coordinated state of the ferric heme. As water is a weak ligand for the ferrous heme, the reduced ferrous CYP3A4 is predominantly in the HS five-coordinated state. On substrate binding the water molecule coordinated to ferric LS can be displaced, leading to the formation of five-coordinated ferric HS iron.<sup>13</sup> This makes it easier for the substrate bound protein to be reduced, as the free energy difference between substrate bound five coordinated ferric HS and five coordinated ferrous HS is lower than substrate free ferric LS and ferrous HS. This is manifested in an increase in the redox potential of CYP3A4 on binding substrates. The stronger the ability of the substrate to perturb the water ligation to the ferric heme, the more pronounced is the spin state shift resulting in the increase in the redox potential.

We found a linear free energy relationship between the formal potential ( $E^\circ$ ) observed vs. the free energy change  $\Delta G = RT \ln K_{SPIN}$  of the ferric spin state equilibrium for both CYP3A4 and CYP 101<sup>2c</sup> (Figure 2) where  $K_{SPIN}$  is the ratio of the high spin and low spin fraction of

the ferric protein. Interestingly, CYP3A4 in Nanodiscs displays the same slope as that previously determined for the soluble CYP101, but with a uniform shift to higher redox potential, demonstrating that the modulation of heme redox potential through effect on the ferric spin equilibrium is of similar origin for both proteins.

The local dielectric constant can also play an important role in determining the absolute redox potential of the heme protein as ferrous heme is neutral compared to a ferric heme which has a net positive charge.<sup>12</sup> The redox potential values measured for CYP3A4 in Nanodisc are relatively more positive compared to those reported for soluble CYP101, Figure 2. This right-shift in the linear free energy plot reflects the more non-polar environment of the heme center in the membrane. Such effects have been discussed in the literature for other heme proteins. 12b, 12c

In summary, we show that spectro-potentiometry of membrane bound cytochrome P450s can be successfully achieved using the Nanodisc system. Multiple redox cycling of CYP3A4-Nanodiscs is reversible, without any conversion to the inactive P420 form. We report a significant increase in CYP3A4 redox potential upon binding some Type I substrates, and show a common linkage between substrate binding, the ferric spin state equilibrium and overall redox potential that is shared by both soluble and membrane bound P450s. These linkages can reflect a substrate dependent control of metabolism, providing a means for avoiding unwanted production of toxic reduced oxygen species in the absence of substrate.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


## Acknowledgements

We acknowledge Dr. Iliia Denisov and Dr. Mark A. McLean at the University of Illinois for helpful discussions. This research was supported by NSF (EEC-0118025) and NIH GM31756.

## References


1. (a) Guengerich FP. Annual Review of Pharmacology and Toxicology 1999;39:1–17. Guengerich, FP. Cytochrome P450: Structure Mechanism, and Biochemistry. 3rd. Ortiz de Montellano, PR., editor. Kluwer Academic/Plenum Publishers; New York: 2005. p. 377-530.
2. (a) Sligar SG. Biochemistry 1976;15:5399–5406. [PubMed: 187215] (b) Sligar SG, Gunsalus IC. Proc Natl Acad Sci (USA) 1976;73:1078–1082. [PubMed: 1063390] (c) Fisher MT, Sligar SG. J Am Chem Soc 1985;107:5018–5019.
3. Johnson DL, Conley AJ, Martin LL. J Mol Endocrinol 2006;36:349–359. [PubMed: 16595705]
4. (a) Safo MK, Nasset MJM, Walker FA, Debrunner PG, Scheidt WR. J Am Chem Soc 1997;119:9438–9448. (b) Nasset MJM, Shokhirev NV, Enemark PD, Jacobson SE, Walker FA. Inorg Chem 1996;35:5188–5200.
5. (a) Guengerich FP. Biochemistry 1983;22:2811–2820. [PubMed: 6307349] (b) Yamazaki H, Johnson WW, Ueng YF, Shimada T, Guengerich FP. J Biol Chem 1996;271:27438–27444. [PubMed: 8910324] (c) Sligar SG, Cinti DL, Gibson GG, Schenkman JB. Biochem Biophys Res Commun 1979;90:925–932. [PubMed: 228675]
6. Light DR, Orme-Johnson NR. J Biol Chem 1981;256:343–350. [PubMed: 7451443]
7. Nath A, Atkins WM, Sligar SG. Biochemistry 2007;46:2059–69. [PubMed: 17263563]
8. (a) Baas BJ, Denisov IG, Sligar SG. Archives of Biochemistry and Biophysics 2004;430:218–228. [PubMed: 15369821] (b) Denisov IG, Grinkova YV, Baas BJ, Sligar SG. J Biol Chem 2006;281:23313–23318. [PubMed: 16762915] (c) Denisov IG, Baas BJ, Grinkova YV, Sligar SG. J Biol Chem 2007;282:7066–7076. [PubMed: 17213193] (d) Denisov IG, Grinkova YV, McLean MA, Sligar SG. J Biol Chem. 2007 In press

9. (a) Hosea NA, Miller GP, Guengerich FP. *Biochemistry* 2000;39:5929–5939. [PubMed: 10821664]  
(b) Harlow GR, Halpert JR. *Proc Natl Acad Sci USA* 1998;95:6636–6641. [PubMed: 9618464]
10. Nernst equation  $\Delta E = \Delta E^\circ + (2.303 RT/n F) \text{Log}_{10} (C_{\text{OX}}/C_{\text{RED}})$  Where  $\Delta E$  is the observed potential,  $C_{\text{OX}}$  is the concentration of oxidized and  $C_{\text{RED}}$  is the concentration of the reduced species.
11. Dutton PL. *Methods in Enzymology* 1978;54:411–435. [PubMed: 732578]
12. (a) Kassner RJ. *Proc Natl Acad Sci USA* 1972;69:2263–2267. [PubMed: 4506096] (b) Krishtalik LI, Tae GS, Cherepanov DA, Cramer WA. *Biophys J* 1993;65:184–195. [PubMed: 8396453] (c) De Biase PM, Doctorovich F, Murgida DH, Estrin DA. *Chemical Physics Letters* 2007;434:121–126. (d) Hervás M, Ortega JM, De la Rosa FF, Losada M. *Biochem Biophys Res Commun* 1988;152:981–986. [PubMed: 2837192]
13. (a) Tsai R, Yu CA, Gunsalus IC, Peisach J, Blumberg W, Orme-Johnson WH, Beinert H. *Proc Natl Acad Sci USA* 1970;66:1157–1163. [PubMed: 4319883] (b) Champion PM, Lipscomb JD, Munck E, Debrunner P, Gunsalus IC. *Biochemistry* 1975;14:4151–4158. [PubMed: 1182094] (c) Raag R, Poulos TL. *Biochemistry* 1989;28:917–922. [PubMed: 2713354] (d) Denisov IG, Makris TM, Sligar SG, Schlichting I. *Chem Rev* 2005;105:2253–77. [PubMed: 15941214]



**Figure 1.**

The redox titration of CYP3A4 in Nanodiscs is conducted in 100 mM phosphate buffer pH 7.4 at 25°C for substrate free and substrate bound protein. **(A)** For substrate free CYP3A4, the direction of the arrows indicate that the absorption maxima at 548 nm and 408 nm decreases and 569 nm and 415 nm increases during the course of oxidative titration. **(B)** For substrate bound CYP3A4, the absorption maxima at 548 nm and 408 nm decreases while that at 645 nm and 391 nm increases during the course of the oxidative titration. The change in the absorption maxima were used to calculate the percentage of reduced protein. The potential is measured at a 4, 4'-dithio-dipyridine modified gold electrode. **(C)** The percentage of reduced cytochrome CYP3A4 in Nanodiscs vs. the electrode potential is plotted for the (i) substrate free (circles) (ii) erythromycin-saturated (diamonds) (iii) bromocriptine-saturated (triangles) and (iv) testosterone-saturated (squares). The oxidative and reductive cycles of redox potentiometry are shown as closed and open data points. **(D)** The Nernst plot (25° C) for single electron redox function is reported for the substrate free CYP3A4 and substrate bound forms.<sup>10</sup> The zero intercept gives  $E^{\circ}$ , the redox potential of the protein (Table 1) and the slope divided by 59 mV yields  $n$ , the number of electrons involved in the reaction which is 0.8 – 1 for the measurements indicated.



**Figure 2.** Free energy correlation between the CYP3A4 and CYP101 ferric spin state equilibrium and the observed redox potential.

**Table 1**

The formal potential ( $E^{\circ'}$ ) and substrate induced ( $\Delta E^{\circ'}$ ) shifts for CYP3A4-Nanodisc binding to the different substrates as determined from the Nernst plots shown in figure 1D.

Enzyme State	High Spin	$E^{\circ'}$ (mV)	$\Delta E^{\circ'}$ (mV)
Substrate Free	11 %	$-220 \pm 10$	-----
Erythromycin	22 %	$-210 \pm 10$	$+ 10 \pm 5$
Testosterone	92 %	$-140 \pm 5$	$+ 80 \pm 10$
Bromocriptine	93 %	$-137 \pm 5$	$+ 80 \pm 10$